KROS Jun 2024 65.000 put
| Previous close | 7.90 |
| Open | 8.30 |
| Bid | 8.40 |
| Ask | 12.00 |
| Strike | 65.00 |
| Expiry date | 2024-06-21 |
| Day's range | 7.90 - 8.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireKeros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. “On behal
- GlobeNewswire
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that five abstracts will be presented from the KER-050 (elritercept) program at the 29th Annual Congress of the Europ
GuruFocus.comKeros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
Financial Performance Misses Analyst Forecasts Amid Increased R&D Investments
